PDF(Sci-hub)
Abstract：
UNASSIGNED: Hematopoietic stem cell transplantation (HSCT) is an established curative modality for various hematological malignancies and other diseases. Hepatobiliary dysfunction and subsequent sequelae constitute a common cause of morbidity and mortality in post-transplant scenario. However, data among Indian HSCT recipients is lacking.
UNASSIGNED: One hundred and one HSCT recipients (37 prospective and 64 retrospective) were followed up for hepatobiliary dysfunction in the post-transplant period. The causes for hepatobiliary dysfunction were categorized as sinusoidal obstruction syndrome (SOS), formerly known as veno-occlusive disease (VOD); acute and chronic graft-versus- host disease (GVHD); drug-induced liver injury (DILI); viral infections and miscellaneous causes including bacterial, fungal and unknown causes based on clinical and laboratory evidence.
UNASSIGNED: Among the 101 transplants, 56.44% (n = 57) were allogenic transplants, and 43.56% (n = 44) were autologous transplants. Hepatobiliary dysfunction was observed among 71 (70.30%) patients in first 30 days and overall, among 78 (77.23%) patients. Incidence of hepatobiliary dysfunction was higher among allogenic transplant patients compared to autologous transplants (91.23% vs. 59.09%, p < 0.001). The most common cause of hepatobiliary dysfunction reported was Drug-induced liver injury (DILI). In most cases, however, hepatobiliary dysfunction was multifactorial. Sinusoidal obstruction syndrome (15.79%), acute liver GVHD (31.58%), chronic liver GVHD (33.33%) and viral infection/reactivation (26.32%) were reported only in allogenic transplant patients. 15 (14.85%) patients died of which 14 patients had hepatobiliary dysfunction, commonest cause being infections.
UNASSIGNED: Our study reported a higher incidence of hepatobiliary dysfunction among Indian population post HSCT and was associated with significant mortality. In majority of the cases, the cause is multifactorial and pose a diagnostic dilemma and challenges in therapy.
UNASSIGNED: One hundred and one HSCT recipients (37 prospective and 64 retrospective) were followed up for hepatobiliary dysfunction in the post-transplant period. The causes for hepatobiliary dysfunction were categorized as sinusoidal obstruction syndrome (SOS), formerly known as veno-occlusive disease (VOD); acute and chronic graft-versus- host disease (GVHD); drug-induced liver injury (DILI); viral infections and miscellaneous causes including bacterial, fungal and unknown causes based on clinical and laboratory evidence.
UNASSIGNED: Among the 101 transplants, 56.44% (n = 57) were allogenic transplants, and 43.56% (n = 44) were autologous transplants. Hepatobiliary dysfunction was observed among 71 (70.30%) patients in first 30 days and overall, among 78 (77.23%) patients. Incidence of hepatobiliary dysfunction was higher among allogenic transplant patients compared to autologous transplants (91.23% vs. 59.09%, p < 0.001). The most common cause of hepatobiliary dysfunction reported was Drug-induced liver injury (DILI). In most cases, however, hepatobiliary dysfunction was multifactorial. Sinusoidal obstruction syndrome (15.79%), acute liver GVHD (31.58%), chronic liver GVHD (33.33%) and viral infection/reactivation (26.32%) were reported only in allogenic transplant patients. 15 (14.85%) patients died of which 14 patients had hepatobiliary dysfunction, commonest cause being infections.
UNASSIGNED: Our study reported a higher incidence of hepatobiliary dysfunction among Indian population post HSCT and was associated with significant mortality. In majority of the cases, the cause is multifactorial and pose a diagnostic dilemma and challenges in therapy.
摘要：
造血干细胞移植(HSCT)是对各种血液恶性肿瘤和其他疾病的既定治疗方式。肝胆功能障碍和随后的后遗症是移植后发病率和死亡率的常见原因。然而,印度HSCT接受者缺乏数据。
■在移植后期间，对101例HSCT接受者（37例前瞻性和64例回顾性）进行了肝胆功能障碍随访。肝胆功能障碍的原因被归类为正弦阻塞综合征（SOS），以前称为静脉闭塞性疾病（VOD）；急性和慢性移植物抗宿主病（GVHD）；药物性肝损伤（DILI）；病毒感染和其他原因，包括细菌，基于临床和实验室证据的真菌和未知原因。
■在101例移植中，56.44%(n=57)是同种异体移植，43.56%(n=44)为自体移植。在前30天和总体上，在71例（70.30％）患者中观察到肝胆功能障碍。78例（77.23%）患者。与自体移植相比，同种异体移植患者肝胆功能障碍的发生率更高(91.23%vs.59.09%,p<0.001)。据报道，肝胆功能障碍的最常见原因是药物性肝损伤（DILI）。在大多数情况下,然而,肝胆功能障碍是多因素的。窦性阻塞综合征（15.79％），急性肝GVHD（31.58%），仅在同种异体移植患者中报告了慢性肝GVHD(33.33%)和病毒感染/再激活(26.32%).15例（14.85%）患者死亡，其中14例患者有肝胆功能障碍，最常见的原因是感染。
■我们的研究报告，在HSCT后的印度人群中，肝胆功能障碍的发生率较高，并且与显著的死亡率相关。在大多数情况下,病因是多因素的,在治疗中带来了诊断困境和挑战.
■在移植后期间，对101例HSCT接受者（37例前瞻性和64例回顾性）进行了肝胆功能障碍随访。肝胆功能障碍的原因被归类为正弦阻塞综合征（SOS），以前称为静脉闭塞性疾病（VOD）；急性和慢性移植物抗宿主病（GVHD）；药物性肝损伤（DILI）；病毒感染和其他原因，包括细菌，基于临床和实验室证据的真菌和未知原因。
■在101例移植中，56.44%(n=57)是同种异体移植，43.56%(n=44)为自体移植。在前30天和总体上，在71例（70.30％）患者中观察到肝胆功能障碍。78例（77.23%）患者。与自体移植相比，同种异体移植患者肝胆功能障碍的发生率更高(91.23%vs.59.09%,p<0.001)。据报道，肝胆功能障碍的最常见原因是药物性肝损伤（DILI）。在大多数情况下,然而,肝胆功能障碍是多因素的。窦性阻塞综合征（15.79％），急性肝GVHD（31.58%），仅在同种异体移植患者中报告了慢性肝GVHD(33.33%)和病毒感染/再激活(26.32%).15例（14.85%）患者死亡，其中14例患者有肝胆功能障碍，最常见的原因是感染。
■我们的研究报告，在HSCT后的印度人群中，肝胆功能障碍的发生率较高，并且与显著的死亡率相关。在大多数情况下,病因是多因素的,在治疗中带来了诊断困境和挑战.
